Printer Friendly

COMPANY INFORMATION
Calyx Bio-Ventures Inc. 220-980 1 St W North Vancouver, BC V7P 3N4 Tel: (604) 985-7100 Fax: (604) 980-2501 Contact Name Darrell J. Elliott Industry Biotechnology		Key Executives Darrell J. Elliott, CEO & acting CFO Develops gene-based cell therapies for treatment of genetic disorders and immune-based cell therapies to address unmet medical need in infectious disease and cancer.
FP ADVISOR COVERAGE Calyx Bio-Ventures Inc. • FP Corporate Surveys • FP Directory of Directors • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 309,546 Angiotech Pharmaceuticals, Inc. 302,251 QLT Inc. 132,457 Oncothyreon Inc. 42,678 AEterna Zentaris Inc. 41,056 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX-VEN/CYX $0.09 $0.15 $0.02 n.a. n.a. n.a. n.a. Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 1,409 n.a. $-0.28 Sept. 30/09 30.77% n.a. n.a. $928
ANNUAL FINANCIALS Periods ended: 12m Dec. 31/081 12m Dec. 31/07 12m Dec. 31/06 $000s $000s $000s Operating revenue 127 1,950 1,505 Net income (2,278) 3,951 (14,777) Total assets 1,424 1,815 4,329 $ $ $ Earnings per share* (0.25) 0.40 (1.80) % % % Return on equity (231.50) n.m. n.m.   * Common 1 Results to June 30, 2008, pertain to Chromos Molecular Systems Inc.

COMPANY NEWS

Results for 'Calyx Bio-Ventures Inc.' from past 30 days: No hits. (Links are to articles.)